Humanized Anti-Aβ Antibodies for High-Affinity Aβ1-42 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-β-amyloid antibodies have shown limited effectiveness in treating Alzheimer's disease and other β-amyloid-related disorders, with many failing in clinical trials, highlighting the need for new antibodies with improved affinity and efficacy.
Innovation Solution
Development of anti-β-amyloid antibodies and antigen-binding fragments with novel amino acid sequences, specifically binding to human β-amyloid with high affinity, particularly targeting Aβ1-42 fibrils and monomers, and exhibiting dissociation equilibrium constants of 10^-7 M or less, including murine, chimeric, and humanized variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-β-amyloid antibodies are used, then some initial therapeutic promise is achieved, but clinical trial failure occurs due to insufficient affinity and efficacy
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody's binding characteristics through affinity maturation and engineering. The anti-β-amyloid antibody is designed with specific variable region sequences that enhance binding affinity to β-amyloid aggregates, transitioning from conventional antibodies with moderate affinity to engineered antibodies with significantly improved binding strength and specificity, thereby achieving the required efficacy for clinical success
Solution Approach 2:
The patent employs copying by creating engineered antibody variants based on the original anti-β-amyloid antibody structure. Through recombinant DNA technology and protein engineering, multiple antibody versions with optimized binding properties are generated, allowing selection of the most effective variant for clinical application while maintaining the core therapeutic mechanism
2Quantity of substance
If antibody structure is optimized for higher affinity, then binding strength increases, but development complexity and time increase
Solution Approach 1:
The patent applies segmentation by dividing the antibody development process into distinct stages: initial antibody generation, affinity maturation through sequential rounds of mutation and selection, and final optimization. This segmented approach allows systematic improvement of binding affinity while managing development complexity through structured, stepwise engineering rather than attempting comprehensive optimization simultaneously
Solution Approach 2:
The patent employs preliminary action by pre-selecting antibody candidates with favorable binding characteristics before extensive engineering. The initial antibody is screened and characterized to identify promising leads, and affinity maturation is directed toward specific epitopes on β-amyloid, allowing focused optimization efforts that reduce overall development complexity while achieving high affinity
Data Source
AI summary
Murine, chimeric or humanized anti-Abeta antibody having a specific CDR region, an antigen-binding fragment thereof, a pharmaceutical composition thereof, and usage thereof. Use of a humanized anti-Abeta antibody for the preparation of drugs for the treatment of a disease or disorder (such as Alzheimer's disease) caused by amyloid beta protein.